Literature DB >> 25160502

The presence of androgen receptor elements regulates ZEB1 expression in the absence of androgen receptor.

Steven M Mooney1, Princy Parsana, James R Hernandez, Xin Liu, James E Verdone, Gonzalo Torga, Calvin A Harberg, Kenneth J Pienta.   

Abstract

Zinc finger E-box binding homeobox 1 (ZEB1) is a transcription factor that plays a central role in the epithelial to mesenchymal transition (EMT) of cancer cell lines. Studies on its regulation have mostly focused on the negative 3'UTR binding of miR200c. Interestingly, it has been previously reported that androgen receptor (AR) regulates ZEB1 expression in breast and prostate cancers. In order to validate this, various ZEB1 promoter deletions were cloned into a luciferase reporter system to elucidate the contribution of two putative androgen response elements (AREs). The in vivo contribution of AR was also assessed in cell lines after R1881 treatment using qPCR with prostate specific antigen (PSA) as the positive control. We discovered that AR upregulates the levels of expression of ZEB1 10-fold on a luciferase promoter that only contains the distal ARE. However, when the proximal ARE is included, no additional activation is apparent with AR or its hormone independent variant, AR-V7. Furthermore, we demonstrate here that a promoter construct containing both AREs activates transcription of ZEB1 even in the AR-null cell lines DU145 and PC3. Incubation of the AR-positive cell line, LNCaP with R1881, failed to substantially increase the expression levels of ZEB1. Despite the presence of AREs in the promoter region, it appears that ZEB1 expression can be induced even without AR. In addition, the region around the distal ARE is a potent repressor in AR-null cell lines.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  ANDROGEN RECEPTOR (AR); EPITHELIAL TO MESENCHYMAL TRANSITION (EMT); LUCIFERASE ASSAYS; OVOL1; OVOL2; PROSTATE CANCER; ZEB1/TCF8

Mesh:

Substances:

Year:  2015        PMID: 25160502      PMCID: PMC4717842          DOI: 10.1002/jcb.24948

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  27 in total

1.  Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential.

Authors:  Steven M Mooney; Joseph P Grande; Jeffrey L Salisbury; Ralf Janknecht
Journal:  Biochemistry       Date:  2010-01-12       Impact factor: 3.162

2.  A majority of the cancer/testis antigens are intrinsically disordered proteins.

Authors:  Krithika Rajagopalan; Steven M Mooney; Nehal Parekh; Robert H Getzenberg; Prakash Kulkarni
Journal:  J Cell Biochem       Date:  2011-11       Impact factor: 4.429

3.  The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein.

Authors:  Yu Zeng; Yanan He; Fan Yang; Steven M Mooney; Robert H Getzenberg; John Orban; Prakash Kulkarni
Journal:  J Biol Chem       Date:  2011-02-25       Impact factor: 5.157

4.  Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

Authors:  Rong Hu; Changxue Lu; Elahe A Mostaghel; Srinivasan Yegnasubramanian; Meltem Gurel; Clare Tannahill; Joanne Edwards; William B Isaacs; Peter S Nelson; Eric Bluemn; Stephen R Plymate; Jun Luo
Journal:  Cancer Res       Date:  2012-06-18       Impact factor: 12.701

5.  Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

Authors:  Qianben Wang; Wei Li; Yong Zhang; Xin Yuan; Kexin Xu; Jindan Yu; Zhong Chen; Rameen Beroukhim; Hongyun Wang; Mathieu Lupien; Tao Wu; Meredith M Regan; Clifford A Meyer; Jason S Carroll; Arjun Kumar Manrai; Olli A Jänne; Steven P Balk; Rohit Mehra; Bo Han; Arul M Chinnaiyan; Mark A Rubin; Lawrence True; Michelangelo Fiorentino; Christopher Fiore; Massimo Loda; Philip W Kantoff; X Shirley Liu; Myles Brown
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

6.  The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis.

Authors:  Charles E Massie; Andy Lynch; Antonio Ramos-Montoya; Joan Boren; Rory Stark; Ladan Fazli; Anne Warren; Helen Scott; Basetti Madhu; Naomi Sharma; Helene Bon; Vinny Zecchini; Donna-Michelle Smith; Gina M Denicola; Nik Mathews; Michelle Osborne; James Hadfield; Stewart Macarthur; Boris Adryan; Scott K Lyons; Kevin M Brindle; John Griffiths; Martin E Gleave; Paul S Rennie; David E Neal; Ian G Mills
Journal:  EMBO J       Date:  2011-05-20       Impact factor: 11.598

7.  Transcription factors OVOL1 and OVOL2 induce the mesenchymal to epithelial transition in human cancer.

Authors:  Hernan Roca; James Hernandez; Savannah Weidner; Richard C McEachin; David Fuller; Sudha Sud; Taibriana Schumann; John E Wilkinson; Alexander Zaslavsky; Hangwen Li; Christopher A Maher; Stephanie Daignault-Newton; Patrick N Healy; Kenneth J Pienta
Journal:  PLoS One       Date:  2013-10-04       Impact factor: 3.240

8.  Hypoxia induces EMT in low and highly aggressive pancreatic tumor cells but only cells with cancer stem cell characteristics acquire pronounced migratory potential.

Authors:  Alexei V Salnikov; Li Liu; Mitja Platen; Jury Gladkich; Olga Salnikova; Eduard Ryschich; Jürgen Mattern; Gerhard Moldenhauer; Jens Werner; Peter Schemmer; Markus W Büchler; Ingrid Herr
Journal:  PLoS One       Date:  2012-09-26       Impact factor: 3.240

9.  Androgen Receptor Regulates Transcription of the ZEB1 Transcription Factor.

Authors:  Bynthia M Anose; Michel M Sanders
Journal:  Int J Endocrinol       Date:  2011-12-10       Impact factor: 3.257

10.  Niche inheritance: a cooperative pathway to enhance cancer cell fitness through ecosystem engineering.

Authors:  Kimberline R Yang; Steven M Mooney; Jelani C Zarif; Donald S Coffey; Russell S Taichman; Kenneth J Pienta
Journal:  J Cell Biochem       Date:  2014-09       Impact factor: 4.429

View more
  6 in total

1.  A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients.

Authors:  J L García; R Lozano; I Misiewicz-Krzeminska; J Fernández-Mateos; P Krzeminski; S Alfonso; R A Marcos; R García; F Gómez-Veiga; Á Virseda; M Herrero; D Olmos; J J Cruz-Hernández
Journal:  Clin Transl Oncol       Date:  2017-06-09       Impact factor: 3.405

2.  Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts.

Authors:  James R Hernandez; John J Kim; James E Verdone; Xin Liu; Gonzalo Torga; Kenneth J Pienta; Steven M Mooney
Journal:  Med Oncol       Date:  2015-04-09       Impact factor: 3.064

3.  The transcriptional factor ZEB1 represses Syndecan 1 expression in prostate cancer.

Authors:  Nancy Farfán; Nallatt Ocarez; Enrique A Castellón; Nilo Mejía; Antonio García de Herreros; Héctor R Contreras
Journal:  Sci Rep       Date:  2018-07-31       Impact factor: 4.379

4.  An hTERT/ZEB1 complex directly regulates E-cadherin to promote epithelial-to-mesenchymal transition (EMT) in colorectal cancer.

Authors:  Yong Qin; Bo Tang; Chang-Jiang Hu; Yu-Feng Xiao; Rui Xie; Xin Yong; Yu Yun Wu; Hui Dong; Shi-Ming Yang
Journal:  Oncotarget       Date:  2016-01-05

Review 5.  Phenotypic plasticity in prostate cancer: role of intrinsically disordered proteins.

Authors:  Steven M Mooney; Mohit Kumar Jolly; Herbert Levine; Prakash Kulkarni
Journal:  Asian J Androl       Date:  2016 Sep-Oct       Impact factor: 3.285

6.  Ovol2 induces mesenchymal-epithelial transition via targeting ZEB1 in osteosarcoma.

Authors:  Jijun Liu; Qi Wu; Yonggui Wang; Yulong Wei; Hong Wu; Lijun Duan; Qiang Zhang; Yonggang Wu
Journal:  Onco Targets Ther       Date:  2018-05-22       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.